Michael J. Pontecorvo

Overview

Best Publications

• Use of Florbetapir-PET for Imaging β-Amyloid Pathology

  Christopher M. Clark;Julie A. Schneider;Barry J. Bedell;Thomas G. Beach

  1278
  Citations

• The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

  William E. Klunk;William E. Klunk;Robert A. Koeppe;Julie C. Price;Tammie L. Benzinger;Tammie L. Benzinger

  1185
  Citations

• In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

  Dean F. Wong;Paul B. Rosenberg;Yun Zhou;Anil Kumar

  930
  Citations

• Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

  Christopher M Clark;Michael J Pontecorvo;Thomas G Beach;Barry J Bedell

  914
  Citations

• Four distinct trajectories of tau deposition identified in Alzheimer’s disease

  Jacob W Vogel;Alexandra L Young;Neil P Oxtoby;Ruben Smith

  683
  Citations

• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

  Unknown

  563
  Citations

• The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions

  Raymond T. Bartus;Reginald L. Dean;Michael J. Pontecorvo;Charles Flicker

  539
  Citations

• Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods

  Susan M. Landau;Susan M. Landau;Susan M. Landau;Christopher Breault;Abhinay D. Joshi;Michael Pontecorvo

  511
  Citations

• Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

  Abhinay D. Joshi;Michael J. Pontecorvo;Chrisopher M. Clark;Alan P. Carpenter

  509
  Citations

• Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

  Eric R. Siemers;Karen L. Sundell;Christopher Carlson;Michael Case

  465
  Citations

• Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

  Susan M. Landau;Susan M. Landau;Ming Lu;Abhinay D. Joshi;Michael Pontecorvo

  418
  Citations

• Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

  Adam S Fleisher;Michael J Pontecorvo;Michael D Devous;Ming Lu

  416
  Citations

• Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

  Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Auttawut Roontiva

  410
  Citations

• Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

  Michael J. Pontecorvo;Michael D. Devous;Michael Navitsky;Ming Lu

  357
  Citations

• Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

  S. M. Landau;S. M. Landau;B. A. Thomas;L. Thurfjell;M. Schmidt

  331
  Citations

• Selective memory loss following nucleus basalis lesions: long term behavioral recovery despite persistent cholinergic deficiencies.

  Raymond T. Bartus;Raymond T. Bartus;Charles Flicker;Reginald L. Dean;Michael Pontecorvo

  298
  Citations

• Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

  Rik Ossenkoppele;Rik Ossenkoppele;Ruben Smith;Niklas Mattsson-Carlgren;Colin Groot

  290
  Citations

• Individual differences in aging: Behavioral and neurobiological correlates

  Alicja L. Markowska;William S. Stone;Donald K. Ingram;Jay Reynolds

  289
  Citations

• Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline A multicenter study

  P. Murali Doraiswamy;Reisa A. Sperling;R. Edward Coleman;Keith A. Johnson

  276
  Citations

• Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.

  Keith A. Johnson;Reisa A. Sperling;Christopher M. Gidicsin;Jeremy S. Carmasin

  272
  Citations

• Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease

  Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Napatkamon Ayutyanont

  204
  Citations

• Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

  P M Doraiswamy;R A Sperling;K Johnson;E M Reiman

  204
  Citations

• Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

  Jeffrey L. Cummings;Kate Zhong;Jefferson W. Kinney;Chelcie Heaney

  203
  Citations